SI1185272T1 - Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania - Google Patents

Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania

Info

Publication number: SI1185272T1
Authority: SI; Slovenia
Prior art keywords: carbamoylbenzofuran; cyanoindol; mania; piperazine; butyl
Prior art date: 1999-05-27

Application number

SI200030423T

Other languages

Slovenian (sl)

Inventor

Gerd Bartoszyk

Christoph Seyfried

Amsterdam Christoph Van

Henning B�Ttcher

Ewen Sedman

Original Assignee

Merck Patent Gmbh

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1999-05-27

Filing date

2000-05-16

Publication date

2004-12-31

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8238153&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI1185272(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2000-05-16 Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh

2004-12-31 Publication of SI1185272T1 publication Critical patent/SI1185272T1/en

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics

Landscapes

Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
General Health & Medical Sciences (AREA)
Animal Behavior & Ethology (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Neurology (AREA)
Neurosurgery (AREA)
Biomedical Technology (AREA)
Psychiatry (AREA)
Reproductive Health (AREA)
Endocrinology (AREA)
Pain & Pain Management (AREA)
Obesity (AREA)
Rheumatology (AREA)
Diabetes (AREA)
Hematology (AREA)
Gynecology & Obstetrics (AREA)
Child & Adolescent Psychology (AREA)
Orthopedic Medicine & Surgery (AREA)
Physical Education & Sports Medicine (AREA)
Nutrition Science (AREA)
Hospice & Palliative Care (AREA)
Addiction (AREA)
Oncology (AREA)
Pregnancy & Childbirth (AREA)
Communicable Diseases (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Plural Heterocyclic Compounds (AREA)

SI200030423T 1999-05-27 2000-05-16 Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania SI1185272T1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
EP99109295		1999-05-27
PCT/EP2000/004376 WO2000072832A2 (en)	1999-05-27	2000-05-16	Novel use of 1-[4-(cyanoindol-3yl)butyl]-4-(carbamoyl-benzofuran-5yl)-piperazine and its physiologically acceptable salts
EP00935031A EP1185272B1 (en)	1999-05-27	2000-05-16	Novel use of 1-[4-(5-cyanoindol-3yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania

Publications (1)

Publication Number	Publication Date
SI1185272T1 true SI1185272T1 (en)	2004-12-31

Family

ID=8238153

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
SI200030423T SI1185272T1 (en)	1999-05-27	2000-05-16	Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania
SI200030902T SI1410800T1 (en)	1999-05-27	2000-05-16	Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts

Family Applications After (1)

Application Number	Title	Priority Date	Filing Date
SI200030902T SI1410800T1 (en)	1999-05-27	2000-05-16	Use of 1- 4-(5-cyanoindol-3-yl)butyl -4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiologically acceptable salts

Country Status (31)

Country	Link
US (4)	US6900212B1 (en)
EP (3)	EP1185272B1 (en)
JP (2)	JP4884588B2 (en)
KR (1)	KR100683367B1 (en)
CN (3)	CN1198618C (en)
AR (1)	AR024112A1 (en)
AT (3)	ATE337008T1 (en)
AU (1)	AU771778B2 (en)
BR (1)	BR0010948A (en)
CA (3)	CA2615271C (en)
CY (2)	CY1105750T1 (en)
CZ (1)	CZ295623B6 (en)
DE (3)	DE60030338T2 (en)
DK (3)	DK1410800T3 (en)
ES (3)	ES2330774T3 (en)
HK (1)	HK1048444B (en)
HU (1)	HU229059B1 (en)
IL (2)	IL146707A0 (en)
MX (1)	MXPA01012172A (en)
MY (1)	MY135627A (en)
NO (2)	NO322120B1 (en)
PL (3)	PL199650B1 (en)
PT (3)	PT1185272E (en)
RU (1)	RU2237477C2 (en)
SI (2)	SI1185272T1 (en)
SK (1)	SK287851B6 (en)
TR (1)	TR200103361T2 (en)
TW (1)	TW518218B (en)
UA (1)	UA74337C2 (en)
WO (1)	WO2000072832A2 (en)
ZA (1)	ZA200110485B (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TW518218B (en) *	1999-05-27	2003-01-21	Merck Patent Gmbh	Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
UA76130C2 (en) *	2000-11-20	2006-07-17	Merck Patent Gmbh	Use of compounds combining properties of selective inhibitors of serotonin re-uptake and agonists of 5-ht1a receptor for treatment of irritable bowel syndrome
DE10112151A1 (en) *	2001-03-14	2002-09-19	Merck Patent Gmbh	New 5-(4-(indolyl-alkyl)-piperazino)-benzofuran-2-carboxamides useful e.g. for treating depression, anxiety, psychiatric or cerebral disorders or pain, are 5-HT-1A receptor agonists and 5-HT reuptake inhibitors
UA76758C2 (en) *	2001-06-19	2006-09-15	Мерк Патент Гмбх	Polymorph forms of hydrochloride of 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoyl-benzofuran-5-yl)-piperazine
DE10217006A1 (en) *	2002-04-16	2003-11-06	Merck Patent Gmbh	Substituted indoles
DE10305739A1 (en) *	2003-02-11	2004-08-19	Merck Patent Gmbh	New indolyl-substituted benzofuran derivatives, are 5-HT(1A) agonists and 5-HT reuptake inhibitors useful e.g. as anxiolytic, antidepressant, neuroleptic and/or antihypertensive agents
WO2004082686A2 (en) *	2003-03-13	2004-09-30	Dynogen Pharmaceuticals, Inc.	Use of compounds with combined 5-ht1a and ssri activities to treat sexual dysfunction
EP1732610A2 (en)	2004-03-26	2006-12-20	Baylor University	Targeted serotonin reuptake inhibitors
NZ572585A (en)	2006-05-30	2011-02-25	Astrazeneca Ab	1,3,4-Oxadiazole derivatives as DGAT1 inhibitors
ES2535083T3 (en)	2007-12-20	2015-05-05	Astrazeneca Ab	Carbamoyl compounds as 190 DGAT1 inhibitors
UY32716A (en)	2009-06-19	2011-01-31	Astrazeneca Ab	PIRAZINE CARBOXAMIDE COMPOUNDS USEFUL FOR THE TREATMENT OF DIABETES AND OBESITY
CN102762201B (en)	2009-11-06	2013-12-18	爱思开生物制药株式会社	Methods for treating attention-deficit/hyperactivity disorder
KR101783633B1 (en)	2009-11-06	2017-10-10	에스케이바이오팜 주식회사	Methods for treating Fibromyalgia syndrome
US8623913B2 (en)	2010-06-30	2014-01-07	Sk Biopharmaceuticals Co., Ltd.	Methods for treating restless legs syndrome
US9610274B2 (en)	2010-06-30	2017-04-04	Sk Biopharmaceuticals Co., Ltd.	Methods for treating bipolar disorder
TWI577377B (en) *	2010-09-16	2017-04-11	Ｖｉｉｖ醫療保健公司	Pharmaceutical compositions
WO2012131706A1 (en)	2011-03-20	2012-10-04	Cadila Healthcare Limited	Amorphous form of vilazodone hydrochloride and process for its preparation
CN102949364A (en) *	2011-08-30	2013-03-06	天津药物研究院	Sustained release tablet containing effective component hydrochloric acid vilazodone
US9382233B2 (en)	2012-06-13	2016-07-05	Apotex Inc.	Forms of vilazodone and processes for the preparation thereof
CN102860993A (en) *	2012-10-16	2013-01-09	北京诚创思达医药科技有限公司	Hydrochloric acid vilazodone quick-release tablet and preparation method thereof
WO2014064715A2 (en)	2012-10-22	2014-05-01	Cadila Healthcare Limited	Amorphous form of vilazodone hydrochloride and process for preparing thereof
CN102977083A (en) *	2012-12-17	2013-03-20	南京海纳医药科技有限公司	New crystal form XVII of 1-(4-(5-cyanoindole-3-yl) butyl)-4-(2-carbamyl-benzofuran-5-yl)-piperazine hydrochloride and preparation method of new crystal form XVII
KR20230098711A (en)	2013-01-22	2023-07-04	비스타젠 쎄라퓨틱스, 인크.	Dosage forms and therapeutic uses of l-4-chlorokynurenine
EP2824104A1 (en)	2013-07-12	2015-01-14	Sandoz AG	Process for the preparation of form III of Vilazodone hydrochloride
PT3297619T (en) *	2015-05-22	2022-08-05	Vistagen Therapeutics Inc	Therapeutic uses of l-4-chlorokynurenine

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE4333254A1 (en)	1993-09-30	1995-04-06	Merck Patent Gmbh	Piperidines and piperazines
GB9406857D0 (en) *	1994-04-07	1994-06-01	Sandoz Ltd	Improvements in or relating to organic compounds
DE19514567A1 (en) *	1995-04-20	1996-10-24	Merck Patent Gmbh	Benzofurans
US5763457A (en) *	1995-11-13	1998-06-09	Eli Lilly And Company	Method for treating anxiety
US5914394A (en) *	1997-03-27	1999-06-22	Millenium Pharmaceuticals, Inc.	Methods and compositions for the diagnosis and treatment of neuropsychiatric disorders
US5900420A (en) *	1997-06-19	1999-05-04	Cole; William L.	Method for treating chronic fatigue syndrome and fibromyalgia with buprenorphine
US6470933B1 (en) *	1998-03-09	2002-10-29	Pirelli Pneumatici S.P.A.	Tire containing at least part of an electrical current generator intended for the supply of sensors and/or other electrical devices present within the tire, and method for manufacture the said tire
FR2781671A1 (en)	1998-07-28	2000-02-04	Synthelabo	PHARMACEUTICAL COMPOSITIONS CONTAINING SEROTONIN RECAPTURE INHIBITOR AND THERAPEUTIC USE THEREOF
TW518218B (en) *	1999-05-27	2003-01-21	Merck Patent Gmbh	Pharmaceutical compositions comprising 1-[4-(5-cyanoindol-3-yl)butyl]-4-(2-carbamoylbenzofuran-5-yl)piperazine or its physiologically acceptable salts for use in the treatment of sub-type anxiety disorders
EP1612563A3 (en) *	2001-09-11	2009-12-09	JTEKT Corporation	Magnetic pulser ring
FR2844591B1 (en) *	2002-09-13	2005-04-15	Arvinmeritor Light Vehicle Sys	DEVICE FOR DETERMINING THE MOVEMENT OF A TREE

1999
- 1999-11-15 TW TW088119882A patent/TW518218B/en not_active IP Right Cessation
2000
- 2000-05-16 SI SI200030423T patent/SI1185272T1/en unknown
- 2000-05-16 ES ES06017231T patent/ES2330774T3/en not_active Expired - Lifetime
- 2000-05-16 JP JP2000620944A patent/JP4884588B2/en not_active Expired - Fee Related
- 2000-05-16 IL IL14670700A patent/IL146707A0/en active IP Right Grant
- 2000-05-16 CA CA2615271A patent/CA2615271C/en not_active Expired - Fee Related
- 2000-05-16 DE DE60030338T patent/DE60030338T2/en not_active Expired - Lifetime
- 2000-05-16 EP EP00935031A patent/EP1185272B1/en not_active Expired - Lifetime
- 2000-05-16 PL PL383406A patent/PL199650B1/en unknown
- 2000-05-16 DK DK04001441T patent/DK1410800T3/en active
- 2000-05-16 AU AU50663/00A patent/AU771778B2/en not_active Ceased
- 2000-05-16 CZ CZ20014226A patent/CZ295623B6/en not_active IP Right Cessation
- 2000-05-16 AT AT04001441T patent/ATE337008T1/en active
- 2000-05-16 DE DE60009697T patent/DE60009697T2/en not_active Expired - Lifetime
- 2000-05-16 CA CA002372668A patent/CA2372668C/en not_active Expired - Fee Related
- 2000-05-16 CN CNB008081352A patent/CN1198618C/en not_active Expired - Fee Related
- 2000-05-16 DE DE60042710T patent/DE60042710D1/en not_active Expired - Lifetime
- 2000-05-16 TR TR2001/03361T patent/TR200103361T2/en unknown
- 2000-05-16 HU HU0201275A patent/HU229059B1/en not_active IP Right Cessation
- 2000-05-16 UA UA2001128861A patent/UA74337C2/en unknown
- 2000-05-16 ES ES00935031T patent/ES2219342T3/en not_active Expired - Lifetime
- 2000-05-16 DK DK00935031T patent/DK1185272T3/en active
- 2000-05-16 EP EP06017231A patent/EP1736158B1/en not_active Expired - Lifetime
- 2000-05-16 RU RU2001133342A patent/RU2237477C2/en not_active IP Right Cessation
- 2000-05-16 CA CA2694866A patent/CA2694866A1/en not_active Abandoned
- 2000-05-16 US US09/979,922 patent/US6900212B1/en not_active Expired - Lifetime
- 2000-05-16 PL PL383006A patent/PL200490B1/en unknown
- 2000-05-16 EP EP04001441A patent/EP1410800B1/en not_active Expired - Lifetime
- 2000-05-16 CN CNA2005100544177A patent/CN1679577A/en active Pending
- 2000-05-16 SI SI200030902T patent/SI1410800T1/en unknown
- 2000-05-16 AT AT00935031T patent/ATE263564T1/en active
- 2000-05-16 PT PT00935031T patent/PT1185272E/en unknown
- 2000-05-16 PT PT06017231T patent/PT1736158E/en unknown
- 2000-05-16 KR KR1020017015141A patent/KR100683367B1/en not_active IP Right Cessation
- 2000-05-16 CN CN200910113677A patent/CN101869565A/en active Pending
- 2000-05-16 PL PL352373A patent/PL199516B1/en unknown
- 2000-05-16 PT PT04001441T patent/PT1410800E/en unknown
- 2000-05-16 MX MXPA01012172A patent/MXPA01012172A/en active IP Right Grant
- 2000-05-16 ES ES04001441T patent/ES2271707T3/en not_active Expired - Lifetime
- 2000-05-16 SK SK1646-2001A patent/SK287851B6/en not_active IP Right Cessation
- 2000-05-16 AT AT06017231T patent/ATE438399T1/en active
- 2000-05-16 WO PCT/EP2000/004376 patent/WO2000072832A2/en active IP Right Grant
- 2000-05-16 DK DK06017231T patent/DK1736158T3/en active
- 2000-05-16 BR BR0010948-7A patent/BR0010948A/en not_active Application Discontinuation
- 2000-05-25 MY MYPI20002314A patent/MY135627A/en unknown
- 2000-05-26 AR ARP000102575A patent/AR024112A1/en unknown
2001
- 2001-11-22 IL IL146707A patent/IL146707A/en not_active IP Right Cessation
- 2001-11-26 NO NO20015746A patent/NO322120B1/en not_active IP Right Cessation
- 2001-12-20 ZA ZA200110485A patent/ZA200110485B/en unknown
2003
- 2003-01-23 HK HK03100617.0A patent/HK1048444B/en not_active IP Right Cessation
2004
- 2004-11-23 US US10/994,226 patent/US7371756B2/en not_active Expired - Lifetime
2006
- 2006-04-06 NO NO20061562A patent/NO324230B1/en not_active IP Right Cessation
- 2006-11-02 CY CY20061101575T patent/CY1105750T1/en unknown
2007
- 2007-11-28 US US11/946,149 patent/US7642261B2/en not_active Expired - Fee Related
2009
- 2009-10-14 CY CY20091101063T patent/CY1109472T1/en unknown
- 2009-11-17 US US12/620,049 patent/US20100063062A1/en not_active Abandoned
2011
- 2011-02-10 JP JP2011027903A patent/JP2011148799A/en active Pending

Also Published As

Publication number	Publication date
EP1410800A1 (en)	2004-04-21
HUP0201275A2 (en)	2002-08-28
JP4884588B2 (en)	2012-02-29
EP1185272B1 (en)	2004-04-07
RU2237477C2 (en)	2004-10-10
HK1048444B (en)	2005-12-09
ES2271707T3 (en)	2007-04-16
DK1410800T3 (en)	2006-12-27
PL352373A1 (en)	2003-08-25
HK1048444A1 (en)	2003-04-04
CY1105750T1 (en)	2010-12-22
UA74337C2 (en)	2005-12-15
PT1410800E (en)	2007-01-31
SK287851B6 (en)	2012-01-04
DE60009697D1 (en)	2004-05-13
AU771778B2 (en)	2004-04-01
CN1679577A (en)	2005-10-12
WO2000072832A2 (en)	2000-12-07
PT1185272E (en)	2004-08-31
NO20015746L (en)	2001-11-26
HU229059B1 (en)	2013-07-29
US20080119484A1 (en)	2008-05-22
US20050113386A1 (en)	2005-05-26
US6900212B1 (en)	2005-05-31
HUP0201275A3 (en)	2004-04-28
JP2011148799A (en)	2011-08-04
EP1736158A2 (en)	2006-12-27
KR20020008847A (en)	2002-01-31
DE60009697T2 (en)	2005-04-14
TW518218B (en)	2003-01-21
DK1736158T3 (en)	2009-11-02
AU5066300A (en)	2000-12-18
NO20061562L (en)	2001-11-26
ATE263564T1 (en)	2004-04-15
PL199516B1 (en)	2008-09-30
CY1109472T1 (en)	2012-05-23
ES2330774T3 (en)	2009-12-15
ATE337008T1 (en)	2006-09-15
NO322120B1 (en)	2006-08-14
SK16462001A3 (en)	2002-02-05
US7371756B2 (en)	2008-05-13
CN1361692A (en)	2002-07-31
EP1185272A2 (en)	2002-03-13
EP1736158B1 (en)	2009-08-05
DE60030338T2 (en)	2007-08-16
CA2615271A1 (en)	2000-12-07
CA2615271C (en)	2011-02-15
CN101869565A (en)	2010-10-27
KR100683367B1 (en)	2007-02-15
BR0010948A (en)	2002-04-23
PL199650B1 (en)	2008-10-31
ZA200110485B (en)	2003-06-30
ES2219342T3 (en)	2004-12-01
NO324230B1 (en)	2007-09-10
PT1736158E (en)	2009-11-11
CZ20014226A3 (en)	2002-03-13
MY135627A (en)	2008-05-30
NO20015746D0 (en)	2001-11-26
CZ295623B6 (en)	2005-09-14
US20100063062A1 (en)	2010-03-11
CA2372668A1 (en)	2000-12-07
SI1410800T1 (en)	2007-02-28
MXPA01012172A (en)	2002-07-22
IL146707A0 (en)	2002-07-25
PL200490B1 (en)	2009-01-30
ATE438399T1 (en)	2009-08-15
CA2372668C (en)	2009-11-03
EP1410800B1 (en)	2006-08-23
DK1185272T3 (en)	2004-08-09
AR024112A1 (en)	2002-09-04
JP2003500441A (en)	2003-01-07
TR200103361T2 (en)	2002-05-21
EP1736158A3 (en)	2007-01-03
US7642261B2 (en)	2010-01-05
DE60030338D1 (en)	2006-10-05
CA2694866A1 (en)	2000-12-07
IL146707A (en)	2007-06-03
CN1198618C (en)	2005-04-27
WO2000072832A3 (en)	2001-12-20
DE60042710D1 (en)	2009-09-17

Publication	Publication Date	Title
SI1185272T1 (en)	2004-12-31	Novel use of 1-(4-(5-cyanoindol-3yl)butyl)-4-(2-carbamoylbenzofuran-5-yl)piperazine and its physiological acceptable salts for the treatment of bipolar disorders and mania
IL158631A0 (en)	2004-05-12	4-(phenyl-piperazinyl-methyl) benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1051504A1 (en)	2003-08-08	Use of compounds with 5-ht1a activity useful for treating disorders of the outer retina
ZA200107689B (en)	2002-12-18	1-Arenesulfonyl-2-aryl-pyrrolidine and piperidine derivatives for the treatment of CNS disorders.
IL158704A0 (en)	2004-05-12	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HUP0204050A3 (en)	2004-09-28	Drug combination for the treatment of depression and related disorders comprising mirtazapine and gepirone
IL158703A0 (en)	2004-05-12	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
EP0410114A3 (en)	1992-01-02	Use of 4-(4-(5-fluoro-2-pyrimidinyl)-1-piperazinyl)-1-(4-fluorophenyl)-butanol in pharmaceutical compositions for the treatment of ischemia in brain
IL158632A0 (en)	2004-05-12	4-(phenyl-piperidin-4-ylidene-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HK1057332A1 (en)	2004-04-02	Use of 3-benzoylphenylacetic acid derivatives for the treatment of retinal disorders
IL150290A0 (en)	2002-12-01	The use of mirtazapine for the treatment of sleep disorders
IL158695A0 (en)	2004-05-12	4-(phenyl-piperidin-4-yldine-methyl)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158630A0 (en)	2004-05-12	4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
IL158628A0 (en)	2004-05-12	4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
AU2002354850A1 (en)	2003-05-22	4-(benzylidene-amino)-3-(methylsulfanyl)-4H-(1, 2, 4) triazin-5-one derivatives having a PDE-IV inhibiting and TNF-antagonistic effect for the treatment of cardiac diseases and allergies
IL158629A0 (en)	2004-05-12	4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
PL376713A1 (en)	2006-01-09	Use of piperazine sulfonic acid derivatives as ccr1 antagonists for the treatment of fibrosis, alzheimer disease and other disorders
IL158700A0 (en)	2004-05-12	4-(phenyl-(piperidin-4-yl)-amino)-benzamide derivatives and their use for the treatment of pain, anxiety or gastrointestinal disorders
HUP0202145A3 (en)	2003-02-28	The use of r(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-(4-fluorophenyl)ethyl]-4-piperidinemethanol for the treatment of sleep disorders
IL130994A0 (en)	2001-01-28	Use of 1-[4-(3- trifluoromethylphenyl)- 1,2,3,6-tetrahydropyrid- 1-yl]-2- (6,7-dimethoxynapth-2- yl) ethane for preparing medicines for the treatment of cerebral and neuronal disorders